In a number of P/P patients, standard treatment plans just don’t seem to work so other evidence-based treatments may be prescribed. IVIg or Rituximab two expensive treatments require approval by a patient’s medical plan. Many insurers choose to deny these treatments.
The IPPF and AxelaCare, a national specialty infusion pharmacy, have developed a Patient Advocacy Program to be launched at our Annual Meeting as a special ACTION! Event. AxelaCare’s Insurance Advocates will work with P/P patients and their doctors to get these treatments approved by specific insurance providers. If you have been denied, AxelaCare guides you and your physician through the appeal process using a successful system developed with P/P patients in mind.
This system was tested with two IPPF members seeking IVIg and/or Rituxan who struggled to get these services after a lack of success with lesser treatments. Our partnership was started to help P/P patients understand their health insurance benefits and receive coverage for evidence-based treatments while navigating the insurance maze. AxelaCare knows complex reimbursement issues and high out-of-pocket costs prevent patients from starting and maintaining their therapies.
So, if you would like to encourage coverage from your insurance provider, bring your policy, any denial letters, and any documentation from your doctor suggesting further treatments, to get a FREE consultation, sample letters, supporting articles from one of the IPPF/AxelaCare Advocates! Email Molly at firstname.lastname@example.org. Also, you can email Rebecca at email@example.com to discuss her successful experience with the process.